Major Depressive Disorder With Mixed Features - Extension

Status:	Completed
Conditions:	Depression, Major Depression Disorder (MDD)
Therapuetic Areas:	Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:	No
Age Range:	18 - 75
Updated:	10/14/2017
Start Date:	September 2011
End Date:	October 2013

A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with
mixed features.This clinical study is designed to test how well Lurasidone works to treat
major depressive disorder with mixed features over time.

Inclusion Criteria:

Subject provides written informed consent and is willing and able to comply with the
protocol in the opinion of the Investigator.

Subject has completed 6 weeks of treatment in Study D1050304 (NCT#01421134) or Study
D1050305 (NCT#01423240).

Subject is judged by the Investigator to be suitable for participation in a 12-week
clinical trial involving open-label lurasidone treatment and is able to comply with the
protocol in the opinion of the Investigator.

Exclusion Criteria:

Subject answers "yes" to "Suicidal Ideation" Item 4 or 5 on the C-SSRS (at time of
evaluation) at baseline (Day 43 in Study D1050304 or D1050305).

Subject is considered by the Investigator to be at imminent risk of suicide or injury to
self, others, or property.

We found this trial at

sites

Birmingham Psychiatry Pharmaceutical Studies, Inc.

Birmingham, Alabama 35226

from

Birmingham, AL